Lupin today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Sildenafil for Oral Suspension, 10 mg/mL to market a
generic equivalent of Revatio for Oral Suspension, 10 mg/mL, of Viatris Specialty LLC. The product will be manufactured at Lupin's facility in Goa, India.
Sildenafil for Oral Suspension, 10 mg/mL (RLD Revatio) had estimated annual sales of USD 66 million in the U.S. (IQVIA MAT December 2021).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
